Crossmark

Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

Crossref DOI link: https://doi.org/10.1186/s12935-019-0725-1

Published Online: 2019-01-08

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Fernandez, Marta Llaurado

Dawson, Amy

Hoenisch, Joshua

Kim, Hannah

Bamford, Sylvia

Salamanca, Clara

DiMattia, Gabriel

Shepherd, Trevor

Cremona, Mattia

Hennessy, Bryan

Anderson, Shawn

Volik, Stanislav

Collins, Colin C.

Huntsman, David G.

Carey, Mark S.
Funding

Funding for this research was provided by:

British Columbia Cancer Foundation (1OVRG012)

Canadian Institute of Health Research (136836)
License Information

Text and Data Mining valid from 2019-01-08
More Information

Article History

Received: 19 October 2018

Accepted: 2 January 2019

First Online: 8 January 2019